Home > Result Summaries: Compounds > H5N1 Pandemic Influenza Vaccine > Result Summary for 106750

Result Summary for 106750

Result Summary

Protocol ID:	106750
Clinical Study ID:	106750
Official Title:	Observer-blind monocentric study in adults aged b/w 18-60 yrs to evaluate reactogenicity and immunogenicity of 1 and 2 administrations of pandemic monovalent influenza vaccines administered at different antigen doses & adjuvanted or not.
Phase:	phase 1
Study Indications or Diseases:	Influenza
Generic Name:	H5N1 Pandemic Influenza Vaccine
Trade/Product Name:	Pandemrix
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Leroux-Roels I et al. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine. Lancet. 370 (9587): 580-589. Moris P et al. (2011) H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T cell responses. J Clin Immunol. 31(3):443-454. Leroux-Roels I et al. (2008) Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PlosOne. 3(2): e1665.